Anne Kantardjieff, Ph.D

Vice President at Biogen

Speaker

Anne Kantardjieff, PhD, is Vice President and Head of CMC Development and Regulatory for Biologics and Advanced Therapies at Biogen. She leads global teams responsible for development, technical transfer, and regulatory CMC strategy across a diverse portfolio of biologics and advanced therapy programs, with a focus on scalable manufacturing, inspection-ready supply, and accelerated patient access.

Prior to Biogen, Anne served as Vice President of Manufacturing and MSAT at bluebird bio, where she led end-to-end supply and technical operations supporting four approved gene therapies: Zynteglo, Skysona, Abecma, and Lyfgenia. In this role, she oversaw external manufacturing partnerships, process validation, regulatory inspections, and commercial launch execution across multiple global markets.

Earlier in her career, Anne held leadership roles at Alexion Pharmaceuticals, where she led early- and late-stage process development teams and contributed to the commercialization of Strensiq, Kanuma, and Ultomiris. She holds a PhD in Chemical Engineering from the University of Minnesota and a Bachelor of Engineering in Chemical Engineering from McGill University, and has been an active volunteer with the American Chemical Society’s Biochemical Technology Division, supporting conference programming and professional engagement initiatives.